Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MUPIROCIN

All products: general benefit

Other products in the same Health Canada class (D06AX) — coverage varies; not interchangeable

  • Fusidic acid (Fucidin): general benefit
  • Mupirocin (Stramucin): general benefit
  • Fusidate (Fucidin): general benefit

Taro-Mupirocin · DIN 02279983 · 2% · Oint

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Mupirocin · DIN 02279983 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2007-01-02 Health Canada: Marketed since 2006-07-10 · brand TARO-MUPIROCIN · ATC D06AX09 MUPIROCIN · form Ointment · route Topical · ingredients MUPIROCIN 2 % · company Taro pharmaceuticals inc · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Taro-Mupirocin: Formulary list price $0.5069/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5069 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76560 · Verify on the e-Formulary ↗ (DIN 02279983)

Source record
DIN 02279983: Taro-Mupirocin Raw flags: sec3=Y Item: 840404008; group id 813; item number 1992; lccId None; manufacturer id TAR Source form: Oint; strength: 2% Recorded listing: General benefit Source prices (unrounded): $0.5069; ministry $0.5069 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02279983 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76560
Interchangeable products
Bactroban · DIN 01916947 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (84:04:04 Antibiotics) and how they are covered

Matched class: 84:04:04 Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE, FUSIDIC ACID, MUPIROCIN CALCIUM, SODIUM FUSIDATE 84:04:04 Antibiotics

FUSIDIC ACID

· 2 products · General benefit · strengths: 2% · Cr

MUPIROCIN CALCIUM

· 1 products · General benefit · strengths: 2% w/w · Cr

SODIUM FUSIDATE

· 2 products · General benefit · strengths: 2% · Oint

CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE

· 4 products · General benefit · strengths: 1% & 5% · Gel, Top Gel

CLINDAMYCIN PHOSPHATE & ADAPALENE & BENZOYL PEROXIDE

· 1 products · Limited Use, codes 724 · strengths: 1.2% w/w & 0.15% w/w & 3.1% w/w · Top Gel Pump

CLINDAMYCIN

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% · Top Sol Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:04
Full class listing Related classes: 84:04:08 Fungicides, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Taro-Mupirocin (mupirocin) is considered appropriate for the topical treatment of the following when caused by sensitive strains of staphylococcus and streptococcus species:  impetigo  superficially infected dermatoses  lesions which are moist and weeping For abrasions, minor cuts and wounds, the use of Taro-Mupirocin (mupirocin) may prevent the development of infections by sensitive Gram-positive organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Taro-Mupirocin (mupirocin) and other antibacterial drugs, Taro-Mupirocin (mupirocin) should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. https://pdf.hres.ca/dpd_pm/00047763.PDF PM date: not printed or not captured Source product: TARO-MUPIROCIN; DIN 02279983; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.